Apraglutide is a synthetic peptide commercialized by VectivBio, with a leading Phase III program in Short Bowel Syndrome. According to Globaldata, it is involved in 12 clinical trials, of which 5 were completed, 4 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Apraglutide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Apraglutide is expected to reach an annual total of $391 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Apraglutide (FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route as a powder and solution for solution for injection. The drug candidate is a long acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was under development for the treatment of chemotherapy-induced gastro-intestinal mucositis.
VectivBio is biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for for severe rare conditions with high unmet medical need. The company’s lead product candidate GLP-2, targeting short bowel syndrome. VectivBio is headquartered in Basel, Switzerland.
The operating loss of the company was US$86.7 million in FY2021, compared to an operating loss of US$57.3 million in FY2020. The net loss of the company was US$87 million in FY2021, compared to a net loss of US$59.9 million in FY2020.
For a complete picture of Apraglutide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.